The microRNA miR-504 targets TP53 mRNA encoding the p53 tumor suppressor. miR-504 resides within the fibroblast growth factor 13 (FGF13) gene, which is overexpressed in various cancers. We report that the FGF13 locus, comprising FGF13 and miR-504, is transcriptionally repressed by p53, defining an additional negative feedback loop in the p53 network. Furthermore, we show that FGF13 1A is a nucleolar protein that represses ribosomal RNA transcription and attenuates protein synthesis. Importantly, in cancer cells expressing high levels of FGF13, the depletion of FGF13 elicits increased proteostasis stress, associated with the accumulation of reactive oxygen species and apoptosis. Notably, stepwise neoplastic transformation is accompanied by a gradual increase in FGF13 expression and increased dependence on FGF13 for survival ("nononcogene addiction"). Moreover, FGF13 overexpression enables cells to cope more effectively with the stress elicited by oncogenic Ras protein. We propose that, in cells in which activated oncogenes drive excessive protein synthesis, FGF13 may favor survival by maintaining translation rates at a level compatible with the protein qualitycontrol capacity of the cell. Thus, FGF13 may serve as an enabler, allowing cancer cells to evade proteostasis stress triggered by oncogene activation.
The microRNA miR-504 targets TP53 mRNA encoding the p53 tumor suppressor. miR-504 resides within the fibroblast growth factor 13 (FGF13) gene, which is overexpressed in various cancers. We report that the FGF13 locus, comprising FGF13 and miR-504, is transcriptionally repressed by p53, defining an additional negative feedback loop in the p53 network. Furthermore, we show that FGF13 1A is a nucleolar protein that represses ribosomal RNA transcription and attenuates protein synthesis. Importantly, in cancer cells expressing high levels of FGF13, the depletion of FGF13 elicits increased proteostasis stress, associated with the accumulation of reactive oxygen species and apoptosis. Notably, stepwise neoplastic transformation is accompanied by a gradual increase in FGF13 expression and increased dependence on FGF13 for survival ("nononcogene addiction"). Moreover, FGF13 overexpression enables cells to cope more effectively with the stress elicited by oncogenic Ras protein. We propose that, in cells in which activated oncogenes drive excessive protein synthesis, FGF13 may favor survival by maintaining translation rates at a level compatible with the protein qualitycontrol capacity of the cell. Thus, FGF13 may serve as an enabler, allowing cancer cells to evade proteostasis stress triggered by oncogene activation.
proteostasis | p53 | miR-504 | FGF13 | ribosomal biogenesis M icroRNAs (miRNAs) are endogenous noncoding small RNA molecules (∼22 nucleotides) that regulate gene expression, particularly at the posttranscriptional level (1) . Interestingly, many miRNAs reside within introns of protein-coding genes and are often derived from a common primary transcript that also gives rise to the mature mRNA of their host gene (2) . In such cases, the miRNA biogenesis machinery excises the miRNA precursor (pre-miRNA) from the intron, eventually converting it into the mature miRNA (3) . miR-504 is an intronic miRNA that targets TP53 mRNA encoding the p53 tumor suppressor protein (4) . miR-504 reduces p53 mRNA and protein levels and attenuates cellular p53 activity. p53 serves as a major barrier against cancer, acting primarily as a transcription factor that regulates cell-fate decisions, including cell death and cellular senescence, as well as metabolic homeostasis (5-7). As a consequence of its ability to down-regulate p53, miR-504 overexpression hampers p53-mediated responses such as cellcycle arrest and apoptosis and promotes tumorigenesis (4) .
Intriguingly, miR-504 resides within an intron of the fibroblast growth factor 13 (FGF13) gene (Fig. S1A ), a member of the FGF homologous factors (FHF) family. The proteins comprising this family (FGF11, FGF12, FGF13, and FGF14, also called FHF3, FHF1, FHF2, and FHF4, respectively) bear substantial sequence homology to the core region of the canonical FGF superfamily but differ from the other FGF proteins in their inability to activate FGF receptors and thus to function as "real" growth factors (8) . Indeed, the FHFs are intracellular proteins that interact with various intracellular partners (9, 10) .
FGF13 (FHF2), originally cloned from an ovarian cancer cell line library, is conserved among vertebrates and is normally expressed most abundantly in the brain (10-13). The FGF13 gene generates a number of transcripts arising through alternative splicing and distinct transcription start sites (14) and differing from each other in their 5′ exons; these isoforms are commonly referred to as "1S" (FGF13 1A), "1U" (FGF13 1B), "1V," "1Y," and "1V+1Y" (Fig. S1A ). These variants are differentially expressed in tissues and localize to diverse cellular compartments (15) , suggesting that they may possess distinct properties and functions. Interestingly, FGF13 is overexpressed in several types of cancer (16, 17) .
Intronic miRNAs have roles that may complement (18, 19) or sometimes actually antagonize those of their host genes (20) . We now show that expression of the FGF13 locus, including miR-504, is negatively regulated by p53. Thus, inhibition of miR-504 expression by p53 defines a p53-regulatory negative feedback loop. Importantly, we demonstrate that elevated expression of FGF13 in cancer-derived cells contributes to their survival. We show that the FGF13 1A protein is a nucleolar inhibitor of rRNA synthesis, and its down-regulation in cancer cells induces proteostasis stress, reactive oxygen species (ROS) accumulation, and cell death. Our findings are consistent with the conjecture that oncogenic transformation, which pushes the protein synthesis machinery into excessive activity, induces an increase in misfolded or otherwise Significance MicroRNAs (miRNAs) can regulate the amounts of specific proteins by targeting their mRNA. miR-504, which targets the mRNA encoding the p53 tumor suppressor, resides within an intron of the fibroblast growth factor 13 (FGF13) gene. We show that expression of the FGF13/miR-504 locus is repressed by p53, defining an additional p53-regulatory feedback loop. Moreover, we report that the FGF13 protein, whose expression is upregulated in a subset of tumors, is essential for survival of cells derived from such tumors. Remarkably, FGF13 restricts the production of ribosomal RNA and attenuates protein synthesis. By tuning down protein synthesis, FGF13 upregulation might enable oncogene-driven cancer cells to avoid excessive accumulation of potentially toxic aberrant proteins, conferring a survival advantage. This work defines a unique vulnerability of cancer cells. To whom correspondence should be addressed. Email: moshe.oren@weizmann.ac.il.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1614876114/-/DCSupplemental. aberrant proteins. We propose that by attenuating rRNA synthesis, the up-regulated FGF13 1A mitigates oncogene-associated proteostasis stress and facilitates the survival of transformed cells. Thus, although the augmented FGF13 expression in tumors is unlikely to be a cancer driver, it is not merely a passenger, because it allows the cancer cells to cope with undesirable side effects of oncogene activation. As such, FGF13 may be viewed as a cancer facilitator or "enabler," representing an example of nononcogene addiction whose targeted reversal might render tumors more vulnerable (21) .
Results
Expression of the FGF13/miR-504 Unit Is Negatively Regulated by p53.
To determine whether the in vivo expression pattern of miR-504 correlates with that of its FGF13 host gene, we analyzed lung cancer data from the Cancer Genome Atlas (TCGA) project (22) ; indeed, a significant positive correlation was observed (Fig. 1A) . Hence, FGF13 and miR-504 probably share a common primary transcript [or transcripts; the FGF13 gene has multiple transcription start sites (Fig.  S1A) , giving rise to multiple primary transcripts]. Notably, FGF13 mRNA is significantly elevated in a subset of lung adenocarcinomas, relative to normal lung tissue (Fig. 1B) . Likewise, a fraction of nonsmall cell lung carcinomas (NSCLC) display FGF13 amplification and/or overexpression (Fig. S1B) . Moreover, miR-504 is often up-regulated in EGF receptor-mutant NSCLC (23) . These observations suggest that elevated expression of FGF13 and miR-504 may endow a subset of lung tumors with a selective advantage.
To explore the relevance of FGF13 overexpression in lung cancer, we used the human NSCLC cell line H460 expressing abundant FGF13 and miR-504. H460 cells harbor mutant K-Ras protein and retain WT p53. Remarkably, siRNA-mediated p53 silencing increased miR-504 (Fig. 1C) and FGF13 mRNA and protein ( Fig. 1 D  and E) , as also confirmed with a different p53 siRNA (Fig. S1C) . Quantitative PCR (qPCR) analysis revealed that H460 cells express high levels of the 1A isoform, and this expression is up-regulated upon p53 knockdown (Fig. S1D) . Thus, p53 restricts the expression of its negative regulator miR-504 and its host gene FGF13. The underlying mechanism might be indirect, because we could not detect binding of p53 to the FGF13 promoter region in ChIP assays, nor is such binding suggested by previously published ChIP-sequencing data. FGF13 is overexpressed in a subset of lung cancers (Fig. S1B) , suggesting that its up-regulation might benefit the cancer cells. Indeed, transient FGF13 knockdown reduced the clonogenicity of H460 cells ( Fig. 2A) . Remarkably, FGF13-silenced cells displayed a substantial increase in the sub-G1 population, detected by flow cytometry (Fig. 2B) , and in poly(ADP ribose)polymerase (PARP) cleavage (Fig. 2C) , indicative of apoptosis. A similar effect was observed in another FGF13-high NSCLC cell line, H1437 (Fig. S2A) . Of note, FGF13 silencing did not affect miR-504 expression significantly (Fig. S2B) .
Augmented apoptosis also was elicited by siRNA specifically targeting the FGF13 1A isoform (Fig. 2D ). FGF13 knockdowninduced apoptosis was attenuated by the pan-caspase inhibitor z-VAD-FMK (Fig. S2C ), confirming that it was at least partially caspase-dependent. In contrast, p53 depletion did not attenuate FGF13 knockdown-induced apoptosis (Fig. S2D ), implying that p53 is not required for this death. Rather, p53 depletion appeared to augment cell death even further, although the effect did not reach statistical significance (Fig. S2D) . Additionally, phosphorylated p38 and phosphorylated histone 2A variant H2AX (γ-H2AX) were elevated ( Fig. 2C) , indicative of stress and DNA damage, respectively.
Notably, FGF13 silencing increased cellular ROS (Fig. 2E ) 24 h after siRNA transfection (Fig. S2E) . The free radical scavenger N-acetylcysteine (NAC) provided a modest but significant rescue from apoptosis ( Fig. S2F) , suggesting that increased ROS is partly responsible for cell death upon FGF13 downregulation. Remarkably, comparable ROS up-regulation also was elicited by p53 silencing (Fig. S2G) . Hence, both FGF13 and p53 restrict ROS production in these cells.
Overall, these findings suggest that elevated FGF13 supports homeostasis in lung cancer cells, mitigating oxidative stress and promoting survival. FGF13 1A Is a Nucleolar Protein. Although FGF13 1B binding partners have been described (24, 25) , the FGF13 1A interactome remained unexplored. Therefore, U2OS cells expressing low levels of FGF13 were stably transduced with Flag-FGF13 1A, which then was immunoprecipitated and subjected to mass spectrometry analysis to identify putative interactors. Interestingly, these were highly enriched for nucleolar proteins, including nucleolin, B23/nucleophosmin (NPM1), and numerous ribosomal proteins (Fig. 3A) , suggesting, in agreement with an earlier report (15) , that FGF13 1A resides mainly in the nucleolus. Coimmunoprecipitation analysis confirmed the association of Flag-FGF13 1A with several endogenous nucleolar proteins, including ribosomal protein L11 (RPL11) (Fig. 3B ) and the transcription factor upstream binding factor (UBF) (Fig. 3C) , a positive regulator of rRNA synthesis. Subcellular fractionation confirmed binding of Flag-FGF13 to NPM1, nucleolin, and RPL11 in the nucleolar fraction, demonstrated by immunoprecipitation (IP) with Flag ( Fig. 3D) , NPM1 (Fig. S3A ), or nucleolin (Fig. S3B) antibodies.
Indeed, immunofluorescence staining revealed predominantly nucleolar Flag-FGF13 1A localization (Fig. 3E) , with a weak nucleoplasmic signal. Flag-FGF13 1A colocalized closely with UBF in the fibrillar center and the dense fibrillar component (Fig. 3E , Lower); partial overlap with NPM1 in the granular component was observed also (Fig. 3E, Upper) .
Prediction of nucleolar localization sequences (NoLS) (26, 27) suggested that FGF13 1A contains such elements near its N terminus (Fig. S3C) , a region absent in FGF13 isoforms reported to be cytoplasmic (15) . Furthermore, upon actinomycin D-mediated inhibition of rRNA synthesis, FGF13 1A redistributed to the nucleoplasm (Fig. S3D) , like other nucleolar proteins (28) . Notably, removal of soluble cytoplasmic and nuclear proteins through detergent extraction [CytoSKeleton (CSK)] before fixation confirmed the tight nucleolar association of Flag-FGF13, similar to that of nucleolin (Fig. 3F) . IP analysis validated a specific interaction of endogenous FGF13 with nucleolin (Fig. 3G , compare lane 3 with lane 5), and cell fractionation corroborated its nucleolar distribution (Fig. 3H) . Importantly, endogenous FGF13 remained associated with the nucleolar compartment after detergent extraction (Fig. 3I) . Thus, FGF13 1A is a bona fide nucleolar protein.
FGF13 Depletion Augments Nucleolar Size and Increases rRNA and
Protein Synthesis. FGF13 silencing led to a significant increase in average nucleolar size, revealed by fibrillarin, UBF, and NPM1 staining (Fig. 4 A and B ; quantification in Fig. 4 C and D) . The total number of nucleoli per cell was unaffected (Fig. S3E) .
The nucleolus is the site of ribosomal biogenesis, including transcription and processing of rRNA. Nucleolar enlargement is often associated with increased rRNA content (29) . We therefore assessed the impact of FGF13 down-regulation on rRNA synthesis by quantifying 47S precursor rRNA (pre-rRNA). Remarkably, FGF13 knockdown strongly up-regulated 47S pre-rRNA (Fig. 4E) . The effect was most prominent 24 h after transfection and was attenuated at 48 h (Fig. 4F) , probably reflecting adaptation through a negative feedback loop or merely that the cells were gradually undergoing stress-induced apoptosis. In either case, these results imply that elevated FGF13 restricts rRNA synthesis in these cancer cells.
Augmented rRNA production is usually coupled with increased protein synthesis. Therefore we assessed protein synthesis rates, using the puromycin analog O-propargyl-puromycin (OPP), which is incorporated into newly translated polypeptides and can be fluorescently labeled. Indeed, FGF13 depletion augmented protein synthesis (Fig. 5 A and C) , and this augmented synthesis was abolished by the protein synthesis inhibitor cycloheximide (CHX). Quantification of fluorescence intensity by microscopy ( Fig. 5B ) and by FACS (Fig. 5D ) confirmed the increase in newly translated polypeptides. Notably, the effect was more modest than the corresponding increase in rRNA synthesis. FGF13-depleted cells also displayed enhanced mTOR activity, evident by increased phosphorylation of S6 kinase, RPS6, and 4EBP1 (Fig. 5E) .
Next, we performed RNA sequencing (RNA-seq) analysis on H460 cells without and with FGF13 knockdown (Table S1 ). Gene Ontology (GO) enrichment analysis (Table S2) revealed that FGF13 depletion induced processes associated with disrupted protein homeostasis (proteostasis), including the unfolded protein response (UPR) and the heat-shock response (HSR) (Fig. 5F ). Concomitantly, FGF13 depletion led to the accumulation of CCAAT-enhancer-binding protein homologous protein (CHOP) and spliced x-box binding protein-1 (sXBP1) mRNA (Fig. S4) , indicative of an endoplasmic reticulum (ER) stress response.
Exposure to the proteasome inhibitor MG132 augments the accumulation of aberrant proteins and activates the HSR (30) . We reasoned that combining MG132 with FGF13 knockdown might further exacerbate proteostasis stress. Indeed, combined treatment resulted in augmented HSR, exemplified by up-regulation of heat-shock protein A6 (HSPA6) mRNA (Fig. 5G) encoding the heat-shock 70-kD protein (HSP70) family member HSP70B′, which localizes to the nucleolus upon heat shock (31) .
Together, these observations imply that elevated FGF13 can protect cancer cells against proteostasis stress, probably by tuning down protein synthesis and thereby avoiding excessive emergence of aberrant polypeptides. (Fig. 6A ). miR-504 followed the same trend (Fig. 6B) , suggesting positive selection for elevated expression of the FGF13 locus during transformation. In further support of selection, rather than direct up-regulation, transient overexpression of H-Ras V12 in WI-38 Fast cells did not increase FGF13 mRNA (Fig. S5A) . Actually, oncogenic Ras was reported to repress FGF13 expression in other cells (35 (Fig.  6D) . Concomitantly, FGF13 1A-silenced WI-38
Ras cells displayed elevated phospho-p38 and cleaved PARP and a marked increase in the sub-G1 subpopulation (Fig. 6E) , indicative of exacerbated stress-induced apoptosis. Of note, silencing all FGF13 isoforms together did not exert a stronger effect than silencing FGF13 1A alone (Fig. S5 C and D) . As expected, FGF13 siRNA did not affect the viability of WI-38 slow cells (Fig. S5E) , which hardly express FGF13 mRNA. In agreement with its effects on ROS and apoptosis, FGF13 1A depletion reduced the clonogenicity of WI-38 Ras cells more than that of WI-38
Fast cells (Fig. 6 F and G) . Thus, WI-38 cells accrue a gradual increase in FGF13 expression as they progress along the transformation axis and become increasingly "addicted" to FGF13 overexpression as a survival mechanism.
To address the impact of FGF13 up-regulation during Ras-induced transformation more directly, WI-38 Fast cells were transduced with H-Ras V12 , either alone or in combination with FGF13 1A. Acute H-Ras V12 overexpression led to a substantial reduction in cell number (Fig. 6H, Upper) , in association with increased cell death as assessed by propidium iodide uptake (Fig. S5F) . Notably, WI-38
Fast cells have silenced p16 and p14 ARF expression (32) and tend to undergo apoptosis, rather than senescence, upon Ras hyperactivation (34).
Concomitantly, Ras
V12 decreased the clonogenic survival of WI-38
Fast cells (Fig. 6H) . Thus, FGF13 1A overexpression reduced H-Ras V12 -induced cell death, mitigated the decrease in cell number, restored the clonogenic capacity of H-Ras V12 -infected cells, and enabled the retention of higher mutant Ras expression (Fig. S5G) .
Hence, although FGF13 1A expression is not directly modulated by activated Ras, it is gradually up-regulated during stabilization of the transformation process, enabling mutant Rasexpressing cells to cope better with oncogene-induced stress.
Discussion miR-504 is a negative regulator of p53, directly targeting p53 mRNA and quenching p53 levels and activity (4) . In agreement with a putative oncogenic role, miR-504 is overexpressed in a variety of cancers (4, (37) (38) (39) (40) . However, relatively little is known about the mechanisms that control miR-504 expression, beyond its downregulation by the secreted factors CTGF and TFF1 (38, 39) . We now show that miR-504, along with its host gene FGF13, is subject to constitutive transcriptional repression by p53. This finding is consistent with an earlier study, in which MMTV-Wnt-induced mouse mammary tumors emerging on a p53 +/− background were observed to produce more miR-504 than tumors developing in p53 +/+ mice (41) . The p53-miR-504 negative feedback loop adds a module to the p53 network, possibly acting to boost p53 protein levels further in response to p53-activating signals.
Notably, FGF13-mediated regulation of cell survival does not require WT p53, as observed in H1437 cells harboring mutant p53 (R267P) or upon p53 down-regulation in WT p53 H460 cells. This observation is particularly relevant given the high prevalence of TP53 mutations in NSCLC (42) .
Our study reveals an additional important activity of FGF13. We show that FGF13 1A resides primarily in the cell nucleolus, where it represses rRNA synthesis. Notably, FGF13 1A interacts with UBF, a key mediator of rRNA transcription, suggesting that FGF13 1A may directly inhibit UBF and thereby compromise the ability of RNA polymerase I (Pol I) to transcribe the rDNA genes. In addition, FGF13 may affect RNA Pol I activity by binding nucleolin, whose interaction with RNA Pol I is required for RNA Pol I-mediated transcription (43) . Although our study highlights the impact of FGF13 1A, possible contributions of other FGF13 isoforms should not be disregarded. Indeed, some FGF13 isoforms have been associated with cisplatinum resistance (44) . Moreover, in neurons, FGF13 1B regulates microtubule dynamics and facilitates cell migration (24) . Hence, the loss of p53 function also may promote cancer by up-regulating other FGF13 isoforms.
FGF13 is overexpressed in several types of cancer, including pancreatic endocrine carcinoma (17) , melanoma (16) , multiple myeloma (45) , and lung cancer (this study). FGF13 overexpression might have suggested that FGF13 plays an oncogenic role, a notion seemingly consistent with the repression of its expression by p53. However, we demonstrate here that FGF13 inhibits rRNA and global protein synthesis, as reported for canonical tumor suppressors such as p53 and Arf (46, 47) . Conversely, many oncogenes promote ribosomal biogenesis and protein synthesis to facilitate cell growth and proliferation.
So how does one rationalize FGF13 overexpression in cancer? Our study implies that FGF13 up-regulation is not required to drive . Data are shown as means ± SD from 15 cells per condition, from two independent experiments. ***P < 0.001. (E and F) H460 cells were transfected as in A and B, and RNA was extracted 24 (E) or 48 (F) h after transfection and subjected to qPCR analysis of 47S pre-rRNA and FGF13 mRNA, normalized to GAPDH. Data are expressed as mean ± SD from three independent experiments. **P < 0.01, *P < 0.05.
cancer but rather helps the emerging cancer cells to cope with the unwelcome consequences of oncogene activation. Specifically, many oncogenes, as exemplified by c-Myc, BRAF, and Ras, elicit a substantial increase in the rate of protein synthesis; although facilitating cell proliferation, this increased synthesis also overburdens the cellular protein quality control mechanisms, eventually giving rise to ER stress and proteotoxic stress (48) (49) (50) . Furthermore, mutations in protein-coding regions, frequent in cancer, also increase the load of aberrant proteins and the risk of proteotoxic stress; in that regard, it is remarkable that FGF13 overexpression is observed in lung cancer and melanoma, two cancer types harboring extensive somatic mutations. The challenge to proteostasis in tumor cells may be exacerbated further by the presence of DNA duplications, deletions, and copy number variations, causing imbalance in the stoichiometry of multisubunit complexes (51) . We propose that FGF13 up-regulation dampens this proteostasis stress by tuning down the rate of protein synthesis, eventually bringing it to a level that represents a compromise between the need to produce more proteins and the ability of the cancer cell to evade lethal proteotoxic stress. Indeed, translational attenuation can improve translation fidelity, allowing proper folding of newly synthesized peptides and reducing the load on the protein quality control machinery (52) .
Furthermore, perturbed proteostasis produces ROS that eventually might trigger apoptosis (53) . By moderating the or control siRNAs. GO terms belonging to biological processes were sorted by P values. (G) RNA was isolated from cells transfected as in E and treated or not with 50 μM MG132 (MG) for 4 h. HSPA6 mRNA was quantified by qPCR and normalized to GAPDH. Data are shown as the mean ± SD of three independent experiments. **P < 0.01, *P < 0.05. increase in protein synthesis and quenching ROS accumulation, FGF13 might support cancer cell survival without compromising the other cancer-promoting effects of activated oncogenes. Of note, FGF13 is also overexpressed in cell lines derived from multiple myeloma (45), a malignancy characterized by persistent proteostasis stress and highly reliant on mechanisms that cope with such stress (54).
It is also conceivable that different components of the protein synthesis machinery, whose levels are tightly coordinated in normal cells, become differentially deregulated upon oncogenic activation, creating a chronic imbalance. Of note, excessive accumulation of nascent rRNA can directly cause DNA damage by forming rRNA:rDNA hybrids (55) . Thus, the incipient cancer cell may remedy an imbalance between different components of the protein Fast cells infected as described above. After 8 d of drug selection cells were seeded in triplicate at an equal cell density in six-well plates and were maintained without drug for an additional 11 d. (Bottom) Colonies then were stained with crystal violet, scanned, and quantified as described in SI Materials and Methods. ***P < 0.001. biosynthetic machinery by selectively tuning down the component that is most aberrantly up-regulated. We propose that when that component is rRNA transcription, remedy can be achieved by increasing FGF13, thereby putting an adjustable brake on rRNA synthesis. This effect is reminiscent of RUNX1 mutations in myelodysplastic syndrome, which reduce rRNA synthesis and ribosomal biogenesis, tune down p53 levels, and render hematopoietic stem cells more resilient to stress-induced apoptosis (56) . Interestingly, the PHF6 protein, which, like FGF13, interacts with UBF and represses rRNA synthesis (55) , is overexpressed in B-cell lymphoma and has been suggested to play a role in progression of this malignancy (57) , often driven by c-Myc hyperactivation.
As shown here, stepwise transformation is accompanied by progressive up-regulation of FGF13, along with increased dependence on FGF13 for buffering excessive ROS and for survival. Introduction of oncogenic Ras into WI-38
Fast cells triggers extensive apoptosis and senescence; only a minor fraction of the cells escape these failsafe checkpoints, eventually giving rise to stably transformed progeny (34) . Our data suggest that FGF13 up-regulation is selected for during this stabilization period, because it enables the cancer cells to cope more effectively with the chronic proteostasis stress imposed by Ras activation. In the course of this process, the transformed cells might become addicted to high levels of FGF13, as indicated by their propensity to undergo apoptosis upon FGF13 depletion.
In nontransformed cells, negative regulation of FGF13 by p53 may serve to ensure the robustness of protein homeostasis. Transient attenuation of p53 activity, which may be desirable under particular physiological conditions (e.g., early embryonic development, wound healing), might endanger the cell by allowing excessive ROS accumulation (58) (see also Fig. S2E ). Concurrent transient up-regulation of FGF13 resulting from attenuated p53 activity may help avert these undesirable consequences by providing an alternative layer of protection. This concerted action is made even more effective by the simultaneous up-regulation of miR-504, which reinforces the quenching of p53 activity. Importantly, we surmise that in normal cells this circuit is dynamically regulated, temporally and spatially, assuring its transient nature. However, cancer cells that retain WT p53 might co-opt this mechanism and fix it in an "on" state, thereby blunting p53 by the excessive miR-504 and simultaneously gaining FGF13-mediated protection against potential proteostasis stress imposed by oncogenic events. Such cells will be more likely to possess a long-term competitive advantage.
In sum, although FGF13 is highly unlikely to play a role in driving cancer, our findings suggest that it nevertheless is a facilitator of cancer progression. In fact, FGF13 may be viewed as an enabler, enabling the emerging tumor cells to cope with the stressful impact of cancer-associated deregulation of key cellular processes. Such enablers allow the cancer cell to reset its metabolic balance and achieve higher biosynthetic rates without going overboard. Concomitantly, these cells acquire an addiction to the enabler, as shown for other buffering proteins such as molecular chaperones (21, 59) , thus positioning such enablers as potential targets for cancer therapy.
Materials and Methods
Cell Culture and Chemicals. All cell lines used in this study were grown and maintained as described in SI Materials and Methods.
Transfections and Infections. siRNA transfections were performed with Dharmafect 1 reagent (Dharmacon) according to the manufacturer's protocol. siRNAs for FGF13 and p53 were purchased as SMARTpools, and FGF13 1A was purchased as a single oligo (GGCAAGACCAGCUGCGACAUU) from Dharmacon. All siRNA oligos were used at a final concentration of 20 nM except for doubleknockdown assays in which 10 nM of each siRNA was used.
Retroviral infection of WI-38 Fast cells was performed as previously described (34) . Hygromycin selection was initiated 48 h after infection.
Flow Cytometry. Cell-cycle analysis and measurement of endogenous cellular ROS were performed with propidium iodide staining or with the ROS-sensitive dye 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular Probes), respectively, as described in SI Materials and Methods.
Clonogenic Assay. Six hours after transfection with siRNAs, cells were trypsinized and reseeded in six-well plates at a density of 3,000 cells per well and then were grown until colonies were visible. For infections, 8 days after drug selection the cells were trypsinized and reseeded in six-well plates at a density of 5,000 cells per well. Staining of colonies and analysis are described in SI Materials and Methods.
IP. For Flag-FGF13 IP, U2OS cells were harvested, washed with ice-cold PBS, and lysed on ice in NET lysis buffer [50 mM Tris·HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA 0.1% Nonidet P-40] supplemented with protease inhibitor mix (Sigma) and phosphatase inhibitor mixture II and III (Sigma). Cells were sonicated in a Bioruptor sonicator (Diagenode), 30 s on and 60 s off for a total of 10 min, and then were centrifuged at 14,000 × g for 10 min at 4°C. After preclearing, lysates were incubated at 4°C for 2-4 h with anti-Flag antibodies covalently attached to beads (Sigma). A 1/20 aliquot of the cleared suspension was taken as input. Next, the beads were washed three times with NET buffer, and elution was carried out using a Flag peptide (Sigma) in PBS when indicated. Samples were resolved by SDS/PAGE followed by Western blotting. Nucleolin IP was performed with anti-nucleolin antibody (Abcam) plus protein A-Sepharose beads (Repligen).
Western Blot Analysis. Immunoblot analysis was performed as previously described (60) . The list of antibodies used is provided in SI Materials and Methods.
Isolation of Total RNA and qPCR. RNA isolation, RT-PCR and qPCR analysis are described in SI Materials and Methods. Primer sequences are detailed in SI Materials and Methods.
Immunofluorescence Staining. Nucleolar proteins were visualized as previously reported (61) and described in SI Materials and Methods.
Cell Fractionation. Cytoplasm, nuclei, and nucleoli were prepared from 10 × 10 6 H460 cells essentially as previously reported (62) and as described in SI Materials and Methods.
Measurement of Nucleolar Diameter. The average diameter of the nucleolus was measured in H460 cells stained by indirect immunofluorescence with antibodies against nucleolar proteins UBF or NPM1 using Zeiss LSM700 confocal laser scanning microscopy and analyzed with ZEN imaging software (Carl Zeiss).
Measurement of Protein Synthesis. Newly translated polypeptides were analyzed by using the puromycin analog OPP (Jena Bioscience) with further fluorescent labeling and were quantified by microscopy and by FACS as described in SI Materials and Methods.
Database Analysis. Lung adenocarcinoma data were generated by the TCGA Research Network (https://cancergenome.nih.gov/) and were downloaded from TCGA data portal. Outliers were eliminated from box plots.
Mass Spectrometry Analysis. The detailed procedure of sample preparation and a description of data processing, searching, and analysis are provided in SI Materials and Methods.
RNA-Seq. Library construction, sequencing, and GO enrichment analysis are described in SI Materials and Methods.
Statistical Analysis. Statistical significance was determined using a two-tailed Student's t test. Unless stated otherwise, the P value was calculated based on three biological replicates.
